12:00 AM
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cervarix: Phase III data

A double-blind, Costa Rican Phase III trial in 5,840 evaluable women aged 18-25 showed that Cervarix led to a 93.3% reduction in prevalent oral HPV types 16 and 18 infection compared to a modified formulation of Havrix...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >